• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Confirmed: Valeant to Buy Dendreon

Article

Following reports last week of a bid, it has now been confirmed that the Canadian company Valeant Pharmaceuticals International Inc will buy Provenge-maker Dendreon.

Valeant Pharmaceuticals International Inc will scoop up bankrupt cancer vaccine maker Dendreon Corp, after no additional qualified bids came forward by Tuesday's deadline, Valeant said.

A potential buyer dropped from the bidding process, three sources close to the sale told Reuters earlier.

Valeant, of Laval, Quebec, will get Seattle-based Dendreon's Provenge cancer treatment and other assets for $400 million in cash.

Complete news on Reuters: http://reut.rs/17hWY2r

Related Videos
Dr Eric Yang
Danielle Roman, PharmD, BCOP, Allgheny Health Network
Dr Eric Yang
Drs Yelena Janjigian and Zev Wainberg | Background image credit: ipopba - stock.adobe.com
Nicoletta Colombo, MD, PhD
Oncology experts at PCOC
Joshua K. Sabari, MD
Joshua K. Sabari, MD
Nicoletta Colombo, MD, PhD
Related Content
© 2026 MJH Life Sciences
AJMC®
All rights reserved.